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shRNAs can trigger effective silencing of gene expression in
mammalian cells, thereby providing powerful tools for genetic
studies, as well as potential therapeutic strategies. Speciﬁc shRNAs
can interfere with the replication of pathogenic viruses and are
currently being tested as antiviral therapies in clinical trials.
However, this effort is hindered by our inability to systematically
and accurately identify potent shRNAs for viral genomes. Here we
apply a recently developed highly parallel sensor assay to identify
potent shRNAs for HIV, hepatitis C virus (HCV), and inﬂuenza. We
observe known and previously unknown sequence features that
dictate shRNAs efﬁciency. Validation using HIV and HCV cell culture
models demonstrates very high potency of the top-scoring shRNAs.
Comparing our data with the secondary structure of HIV shows
that shRNA efﬁcacy is strongly affected by the secondary structure
at the target RNA site. Artiﬁcially introducing secondary structure
to the target site markedly reduces shRNA silencing. In addition,
we observe that HCV has distinct sequence features that bias HCV-
targeting shRNAs toward lower efﬁcacy. Our results facilitate
further development of shRNA based antiviral therapies and
improve our understanding and ability to predict efﬁcient shRNAs.
shRNA optimization | RNA secondary structure
The development of RNA interference (RNAi) technology tocontrol gene expression has revolutionized biology and
promises new therapeutic strategies for a variety of diseases (1).
RNAi involves the endogenous production or artiﬁcial in-
troduction of double-stranded RNA in cells, which can be rec-
ognized by the RNA-induced silencing complex (RISC). RISC
selects one strand of the RNA (guide strand) and discards the
other (passenger strand). Following strand selection, RISC uses
the guide strand to recognize target mRNA substrates and
directs the suppression of the mRNA by degradation and
translational inhibition (2). Endogenous RNAi is triggered by
microRNAs (miRNAs), ∼22 nucleotide (nt) RNAs derived from
longer primary miRNAs (pri-miRNAs). Pri-RNAs are cleaved by
the RNase III Drosha/DGCR8 complex to produce the ∼70-nt
precursor miRNAs (pre-miRNAs) with hairpin-like stem loop
structures. Pre-miRNAs are exported into the cytoplasm by
exportin 5, where they are excised by the RNase III Dicer to
produce the mature small double strand RNAs that are sub-
sequently incorporated into RISC to suppress target mRNAs (3).
RNAi can be artiﬁcially triggered by introduction of synthetic
duplex siRNAs into cells or expression of shRNAs. SiRNAs are
synthetic double-stranded RNAs that mimic the endogenous
Dicer excision product (4). SiRNAs are limited by their transient
depletion and many cell types transfect poorly. ShRNAs are
expressed from viral vectors in a form that mimics the stem-loop
structure of the pre-miRNAs, and allows long-term, stable, and
inheritable depletion of target mRNAs (5, 6). An improved
expression approach is to express shRNAs in the context of
endogenous miRNA transcripts that mimics pri-miRNAs. This
approach allows expression from Pol II promoters and potent
target depletion (7–10).
shRNAs have been applied to developing antiviral therapies in
cell culture (11) and in clinical trials for HIV (12). A major
challenge facing this strategy is that the high mutation rate of
HIV makes it relatively easy for the virus to escape from sup-
pression by mutating the shRNA target site (11). Consequently,
multiple potent shRNAs will be required to prevent the occur-
rence of resistance, analogous to the highly active antiretroviral
therapy (HAART) for HIV (11). In addition, a great concern for
any RNAi application is off-target effects (i.e., the shRNA/
siRNA can down-regulate not only the intended target but also
unintended genes). Using lower doses of shRNAs with higher
potency can reduce possible unwanted side effects without
compromising their on-target effects. All things considered, the
ability to accurately select highly potent shRNAs/siRNAs is key
to the optimal application of RNAi and will improve our ability
to use these molecules therapeutically.
We recently developed a multiplex high-throughput assay to
identify potent shRNAs (13). This “sensor” assay uses a single
vector to coexpress an shRNA and its target sequence fused to
the 3′ UTR of a constitutively expressed ﬂuorescence reporter.
By monitoring the ﬂuorescence intensity, we can measure the
depletion efﬁciency of the shRNA and identify cells that express
potent shRNAs. Combined with large-scale oligonucleotides
synthesis and high-throughput sequencing technology or micro-
array hybridization, this single vector system allows multiplexed
analysis of a large number of shRNA-target pairs. In this study,
we applied the sensor assay to analyze ∼40,000 shRNAs from
tiling the whole genomes of two HIV strains, one hepatitis C
virus (HCV) strain, and one inﬂuenza A virus strain to identify
strong antiviral shRNAs. This analysis uncovered sequence fea-
tures of potent shRNAs and an overall dependence of silencing
efﬁcacy on the secondary structure of the target sequence. We
also observe that distinct genome sequence features of HCV bias
HCV-targeting shRNAs toward lower efﬁcacy compared with
HIV and inﬂuenza A virus.
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Results
Sensor Assay Screen of ∼40,000 shRNAs from Tiling Four Viral
Genomes. The sensor assay enables pooled screening for the
discovery of potent shRNAs from a large number of candidates
(13). Our original study validated the assay by evaluating 20,000
shRNAs from tiling of nine mammalian genes (13). In the present
study we apply this platform to identify potent antiviral shRNAs
from four viral genomes, including two HIV strains: NL43 of
clade B and 1084i of clade C (14), one HCV strain: JFH1 of
Genotype 2a (15), and one H1N1 inﬂuenza A strain: inﬂuenza A
virus A/Puerto Rico/8/34 (PR8). We tiled the genomes to cover
every possible target site in addition to a dozen previously vali-
dated shRNAs, also added as controls for the screen, which
resulted in total 40,458 shRNAs. To construct the library, the
stem-loop sequence of each shRNA was synthesized with a cog-
nate 50-nt target sequence on the same 210-nt oligonucleotide. In
addition, each 210-mer also includes a unique 25-mer barcode
sequence (16) for microarray hybridization and restriction-en-
zyme sites for cloning. A two-step pooled cloning strategy was
used to assemble the library into the pSensor vector, which is
a retroviral vector with a Tet-responsive promoter (TREtight).
The shRNA is under TRE promoter control, and the target se-
quence is constitutively expressed in the 3′ UTR of a ﬂuorescence
reporter (Venus). An engineered DF-1 chicken embryonic ﬁ-
broblast cell line expressing ecotropic retroviral receptor and an
improved reverse Tet-transactivator (rtTA3), termed the ERC
(“Eco-rtTA-chicken”) cell line, was used for the sensor assay. To
achieve 1,000-fold representation of each shRNA, 400 million
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Fig. 1. Sensor assay screen of 40,000 shRNAs targeting four viral genomes. (A) Schematic for construction of the virus sensor library. Four viral genomeswere tiled
using ∼40,000 shRNAs that cover almost every possible target site. This library of 210-mer oligonucleotides that cover the shRNA sequence and cognate 50-nt
target sites were synthesized on one microarray chip and cloned in two steps into the pSENSOR vector. (B) FACS sorting results of the sensor assay. First row: Top
and bottom shRNA controls used for determining the gatings for OnDox conditions. Second row: Top shRNA controls used for determining the gatings for OffDox
conditions. Third and Fourth rows: six sorts of the library. S1, S3, S5: sorts 1, 3, 5 are OnDox conditions and sorting for the low ﬂuorescence population; S2, S4, S6:
sorts 2, 4, 6 are OffDox conditions and sorting for the high ﬂuorescence population. x axis is ﬂuorescence intensity and y axis is normalized cell count. (C) Log2
Sensor enrichment scores of 13 control shRNAs in the library after sort 2, sort 4, and sort 6. Strong shRNAs are highly enriched compared with weak and medium
shRNAs. (D) Comparison of nucleotide frequency of top shRNAs (sensor score>4) and low-scoring shRNAs (sensor <1). The 22-nt guide strand sequence is shown in
dark colors; the 14-nt ﬂanking sequences are shown in pastel colors. The ﬂanking sequences of the reverse complements of the mRNA target region are shown: L
corresponds to the 5′ ﬂanking region and R to the 3′ ﬂank of that reverse-complement strand covering the target sequence. Asterisks indicate positions that have
a signiﬁcant difference between top and low scoring shRNAs (P < 0.01). (E) Average GC content of the 4-nt sliding window of the 22-nt target site (green
background) and the ﬂanking regions, starting from 5′ to 3′ of the mRNA target.
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ERC cells were infected with the retroviral library at a low
multiplicity of infection (MOI = 0.1) to ensure single-copy in-
tegration of the retrovirus in the genome. After neomycin se-
lection, cells went through three cycles of “Ping-Pong” sorting to
select for highly potent shRNAs. Each cycle consisted of a doxy-
cycline on (OnDox) sort for low ﬂuorescence population and
a doxycycline off (OffDox) sort for high-ﬂuorescence population
(Fig. 1B). In the OnDox sort, when shRNA expression is turned
on, potent shRNAs would deplete Venus and shift their host cells
to low ﬂuorescence intensity. While the OffDox sort can elimi-
nate cells with an intrinsically low ﬂuorescence because of in-
tegration in a transcriptionally nonpermissive locus rather than
because of depletion by shRNAs. Cells infected with ﬁve strong
shRNAs (top 5) and ﬁve weak shRNAs (bottom 5) were sorted in
parallel to determine the gating for library sorting (Fig. 1B). We
extracted genomic DNA after sorts 2, 4, and 6 (OffDox) to
measure shRNA abundance by microarray hybridization and
deep sequencing (Fig. S1). Microarray hybridization and deep
sequencing results show a strong correlation (Fig. S2) demon-
strating the utility of both methods for the assay. We observed
that the control shRNAs included in the library show clear sep-
aration after the sorts (Fig. 1C). Weak shRNAs dropped out
starting from early sorts, medium-strength shRNAs show minimal
enrichment after sort 6, and strong shRNAs controls are consis-
tently enriched. We use the sort6 log2 enrichment ratio as the
sensor score for ranking the efﬁcacy of shRNAs.
Top-Scoring shRNAs Display Distinct Sequence Feature.We analyzed
the sequence patterns of the top-scoring shRNAs compared with
the low-scoring shRNAs and observed distinct patterns of base
compositions. The 498 top-scoring hairpins with sensor score >4
display a general enrichment for A/U in the guide strand and a
thermodynamic asymmetry from 5′ to 3′ (Fig. 1E). The 5′ region
of the guide strand is enriched for A/U (positions 1, 2, 3, 4, 5, 6,
10, 12, 13, and 14; P value <0.01) and the 3′ region tends to enrich
for G/C (positions 18, 20; P value <0.01) (Fig. 1D). Guide strand
position 1 is predominantly enriched for U (52% frequency),
which can be explained by the preference for U to bind the RISC
complex (17), but position 20 shows a signiﬁcant depletion of A.
Because this position pairs with position 1 of the passenger strand,
depletion of A would make the passenger strand less likely have a
U′ in the 5′ end, therefore less likely to compete with the guide
strand for loading into RISC. These features conﬁrm similar
observations in our previous sensor screen (13). In addition, we
also observe that the ∼8-nt region ﬂanking the 3′ end of the 22-nt
target site is also enriched for A, which has not been previously
reported. Positions L3, L4, L7, and L8 in particular have ∼38%A,
compared with an average of 31% with the low scoring shRNAs
(P < 0.01) (Fig. 1D). Because this region is immediately adjacent
to the shRNA seed-region binding site, the secondary structure in
this region might affect the binding between shRNA and its tar-
get, which likely caused the sequence bias in this region.
Top-Scoring shRNAs Demonstrate Potent Antiviral Activity. To test
the efﬁcacy of top-scoring HIV shRNAs, we generated HeLa-
CD4 cell lines expressing shRNAs from a single-copy retroviral
integration. We infected these cells with HIV-NL43 virus and
examined the effect of different NL43-targeting shRNAs onHIV-
NL43 virus gene expression. Six top-scoring NL43-targeting
shRNAs (N1 to N6) depleted their target HIV genes by 70–90%,
as measured by RT-PCR (Fig. 2A). In contrast, three low-scoring
shRNAs (N7 to N9) displayed little or no depletion of their target
genes. We also used an HCV cell-culture model (15) to validate
top-scoring shRNAs targeting the HCV-JFH1 strain. Stable
derivatives of Huh7.5.1 cells were generated to express individual
shRNAs from single-copy retroviral integrations. Because the
HCV genome is a single-stranded positive sense RNA that is also
its mRNA, which is translated into a single polypeptide before
further processing, the abundance of each HCV protein should
correlate with the abundance of its mRNA. We used quantitative
ﬂuorescence imaging after immunostaining of the HCV core
protein as a readout for shRNA-depletion efﬁciency. Of the top
10 scoring shRNAs, 7 had potent anti-HCV activity, reducing
viral infection rates > 75% (Fig. 2B). Two low-scoring shRNAs
were also tested: one (J11) has little effect on HCV infection, and
another (J12) is highly cytotoxic, possibly explaining why it
dropped out from the initial screen in the early sorts. Remarkably,
four shRNAs achieved almost complete suppression of viral in-
fection; J9 shRNA, in particular, brought down viral infection to
background levels (Fig. 2C and Fig. S3). We then asked whether
this potent shRNA antiviral effect could be translated to siRNAs.
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Fig. 2. Validation of top-scoring shRNAs in HIV and HCV cell-culture models.
(A) Validation of six top-scoring shRNAs (N1–N6) targeting different HIV NL43
genes by rtPCR after NL43 infection of HeLa-CD4 cells in comparisonwith three
low scoring shRNAs (N7–N9) and a control shRNA targeting ﬁreﬂy luciferase
(FF). (B) Validation of the ten top scoring shRNAs (J1–J10) targeting different
HCV-JFH1 genes by immunostaining of core protein of HCV inHuh 7.5.1 cells in
comparison with a low scoring shRNA (J11) and a control shRNA targeting
ﬁreﬂy luciferase (FF). (C) Immunostaining images of a top-scoring shRNAs J9
targeting HCV and shRNA targeting ﬁreﬂy luciferase were shown. (Left) DAPI
staining showing nuclei of Huh 7.5.1 cells; (Right) staining of HCV core protein.
The numbers are the percentages of cells infected by HCV. (Maginiﬁcation:
20×.) (D) Three validated top shRNAs (J6, J7, J9) and a low-scoring shRNA (J11)
were synthesized as siRNAs. Transfections of the siRNAs converted from top
scoring shRNAs have strong anti-HCV effect comparedwith the low scoring J11
and a negative control siRNA targeting ﬁreﬂy luciferase.
Tan et al. PNAS | January 17, 2012 | vol. 109 | no. 3 | 871
G
EN
ET
IC
S
SiRNAs synthesized based on the sequences of shRNAs recapit-
ulated the highly potent depletion efﬁciency. At 1 nM, siRNAs
based on three top-scoring shRNAs completely suppressed HCV
replication. Even at concentrations as low as 10 pM, two of the
three siRNAs still have signiﬁcant viral suppression activity, with
J9 consistently demonstrating the highest potency (Fig. 2D).
These results clearly demonstrate the ability of the sensor assay to
identify very strong shRNAs. In addition, these shRNA sequences
also convert into highly potent siRNAs.
RNA Secondary Structure Is a Major Determinant of shRNA Efﬁciency.
The secondary structure of the genome of HIV NL43 strain has
been extensively studied using the SHAPE (selective 2’-hydroxyl
acylation analyzed by primer extension) technology (18). We
compared the sensor score and the SHAPE activity score of this
strain and found they have a remarkable correlation. At regions
of high secondary structure and thus low SHAPE reactivity,
correspondingly low sensor scores were detected (asterisks
shown in Fig. 3A). This correlation strongly suggests that shRNA
efﬁcacy is signiﬁcantly reduced by secondary structures formed at
the target site. This correlation also globally validates the results
of the sensor screen. Although in regions with less secondary
structure, and thus high SHAPE reactivity, sensor scores do not
always show a strong degree of correlation. This ﬁnding suggests
that favorable secondary structures of the target site are a nec-
essary but not sufﬁcient condition for shRNAs efﬁcacy.
RNAi Target Shielding as a Method to Rescue RNAi. Based on the
result that secondary structure negatively correlates with shRNA
efﬁcacy, we reasoned that artiﬁcially introducing the formation of
secondary structure should be able to inhibit the depletion by
shRNAs. We named this strategy RNAi target shielding (RTS).
We tested this idea using the pSensor construct by inserting a 10-nt
sequence directly 3′ to the 50-nt sensor sequence (Fig. 3B). If the
10 nt is a randomly scrambled sequence, adding Dox induces
shRNA expression and suppress ﬂuorescence (compare Fig. 3C,
green and yellow curves). However, if the 10 nt is reverse com-
plementary to the 3′ of the 22-nt target site, whenDox is added, the
degree of ﬂuorescence intensity reduction is much less compared
with the vector with a scrambled sequence (compare Fig. 3C, blue
and yellow curves). We tested two top (N4 and N6) and one me-
dium (N10) scoring shRNA using this method. All three cases
demonstrate the capability of the reverse complementary sequence
to inhibit depletion of the Venus ﬂuorescent protein by the
shRNAs. In addition, we observe that in the absence of Dox, the
ﬂuorescence intensity of the RTS construct-expressing cells is
slightly higher than the scrambled construct-expressing cells. This
result is likely because of RTS inhibition of the depletion by the
shRNAs expressed due to low level Tet promoter activity in the
absence of Dox, as the intensity differences (gaps between the red
and green curves in Fig. 3C) correlates with the sensor scores of the
three shRNAs.
HCV-Targeting shRNAs Demonstrate Lower Average Sensor Scores
than HIV and Inﬂuenza A Virus. We analyzed the shRNA sensor
scores of different viruses and found that HCV-targeting
shRNAs have signiﬁcantly lower sensor scores on average (P
value < 0.001). As shown in Fig. 4A, although the sensor score
curves of two HIV strains and inﬂuenza A PR8 are largely
overlapping, the curve of HCV shRNAs shifts to the lower ef-
ﬁcacy end, suggesting some general sequence features that dis-
tinguish HCV from HIV and inﬂuenza A virus. We examined
extensively 28 sequence features that were known to affect the
efﬁcacy of siRNAs (19), and found that ﬁve features could dis-
tinguish HCV from HIV and inﬂuenza A virus, as shown in
Table S1, which likely explain the decreased efﬁcacy of HCV-
targeting shRNAs. All ﬁve features directly correlate with the
GC content of the viral genome. Indeed, the GC content of HCV
is 58%, much higher than the other three viral genomes (42%,
42%, and 43% for HIV NL43, HIV 1084i, and inﬂuenza A PR8,
respectively). One of the ﬁve features (UU at position 1 and 2)
also directly correlates with the frequency of A in the viral ge-
nome. Indeed, the HCV genome contains 20% A, much lower
than other three viral genomes (36%, 35%, and 33% for HIV-
NL43, HIV-1084i, and inﬂuenza A-PR8, respectively). The sig-
niﬁcantly higher GC content and lower A content are likely the
major reasons for HCV-targeting shRNAs’ lower efﬁcacy, be-
cause we observe in our sensor screen that the top-scoring
shRNAs have on average lower GC content and higher A con-
tent in their target sequences (Fig. 4C, red dot). We wondered
how common are the two sequences features among RNA
viruses. We analyzed 55 human RNA viruses and plotted their
GC content against their A/U ratio (A% divided by U%) and
found only ﬁve viruses share the pattern of high GC content and
low A/U ratio, as HCV (Fig. 4C and Table S2). Four of the ﬁve
viruses turned out to primarily infect human liver cells [HCV,
HDV, HEV, and HGV (GBV-C)]. This connection might be
explained by the highly active miRNA machinery in the liver
(20), which may have exerted evolutionary pressure to bias the
nucleotide compositions of the viruses infecting the liver.
Discussion
In this study, we applied an shRNA optimization assay to
genomes of HIV, HCV, and inﬂuenza A virus and identiﬁed
potent shRNAs targeting these pathogenic viruses from ∼40,000
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shRNAs that cover the entire genomes of the four viral strains.
The number of shRNAs used in this screen is twice the number
we screened in our previous study (13), showing that large
number of candidates can be examined in a single experiment.
Using two cell-culture models for viral infection, we validated
the top-scoring shRNAs and demonstrated their potent antiviral
effect. These shRNAs target various genes of the viral genomes;
therefore they could be tested for combinatorial treatment of
viral infection (21, 22). Particularly, shRNAs targeting HCV
demonstrate the ability to almost completely inhibit viral in-
fectivity. This highly potent anti-HCV effect could be translated
to synthetic siRNAs, which show strong antiviral activity at
picomolar concentration. These data highlight the power of the
sensor assay to identify strong shRNAs from a large number of
candidates. Among the top 10 HCV-targeting shRNAs we tested,
three had no anti-HCV effects. These false-positives are likely
because of longer-range interaction of the RNA genome pro-
ducing inhibitory structures or possibly because of the blocking of
the target site by endogenous proteins that bind those sequences.
Our sensor assay screen uncovered several sequence features
signiﬁcantly enriched in top-scoring shRNAs. Several of these
features conﬁrm our previous observations, including thermo-
dynamic asymmetry, high frequency of U at 5′ end of guide
strand, bias for A/U at positions 2, 10, 13, 14, drop-out of A at
position 20, and so forth. In addition, we also found sequence
features not reported before. Notably, the ∼8-nt ﬂanking region
of the target site immediately adjacent to where the 5’ end of
the guide strand binds is enriched for A. This ﬁnding shows the
importance of considering the sequence ﬂanking the guide
strand binding site for predicting strong shRNAs.
We observed a remarkable correlation of the sensor score with
the SHAPE activity score along the whole genome of HIV-
NL43. This ﬁnding clearly demonstrates that target RNA sec-
ondary structure is a major determinant of the efﬁcacy of
shRNA. We found SHAPE provides particularly useful in-
formation for excluding bad shRNAs because of highly struc-
tured target sites. Accordingly, SHAPE activity data, which can
now be measured in a fast and high-throughput fashion (23),
should be helpful for predicting shRNA efﬁcacy. Furthermore,
the ability of the sensor assay using only a 50-nt window to re-
capitulate experimentally derived secondary structure in native
RNAs suggests that the vast majority of secondary structures are
local in nature.
Inspired by these observations, we devised a unique way to
rescue gene expression from the repressive effects of shRNAs by
inserting a short stretch of nucleotide reverse complementary to
the shRNA target site after the 3′ end of the reading frame. We
named this method RNAi target shielding and showed that it can
effectively inhibit depletion by shRNAs.
Comparing the sensor scores of four different viral genomes,
we found that HCV shRNAs have on average lower sensor
scores, indicating unique sequence features that make potent
HCV-targeting shRNAs less frequent. This indication could be
explained by the high GC content and low A content of the HCV
genome. Remarkably, among 55 human ssRNA viruses analyzed,
three of four viruses that share these sequence features with
HCV also use liver cells as their natural hosts. These features are
unlikely to be explained by codon usage as liver shows similar
GC3 content (the GC content of the third nucleotide of codons)
as other tissues (24). We hypothesize these unique sequence
features are the outcome of viral evasion of the active miRNA
machinery in the liver through evolution. Indeed, a large number
of miRNAs are expressed in the liver. In addition, several
miRNAs have been reported to be induced by IFN in liver cells
to inhibit HCV infection (25). To survive the potential sup-
pression by the abundant endogenous miRNAs in liver cells, the
hepatitis viruses might have adapted to the high GC and low A
content to reduce the chance of being inhibited by endogenous
miRNAs. Given the facile delivery of RNAi reagent to the liver
(26–28), we propose this susceptibility of HCV to RNAi could be
exploited by RNAi-based therapy. Our results provide a rich
database for selecting potent shRNAs to that end.
Experimental Procedures
See SI Experimental Procedures for additional experimental details. See
Dataset S1 for the sequences and sensor scores by microarray hybridization
and deep sequencing of the shRNAs used, and Dataset S2 for the genome
sequences of the four viral strains used in this study.
Vectors, Library Construction, and Reporter Cell Lines. We synthesized 40,458
210-mer oligonucleotides on a 55,000 features oligonucleotide array (Agilent
Technology). Each 210-mer contains a 101-nt miR30-shRNA fragment, a 16-nt
sequence containing EcoRI and MluI restriction enzyme sites for inserting the
Venus-coding sequence, a 50-nt sensor cassette that is the target site for the
shRNA, anda25-mer uniquebarcode formicroarrayhybridization followedby
an18-nt primerbinding site. A two-steppooled cloning strategywas used (13).
In the ﬁrst step, the 210-mer was cloned into the pSENSOR vector, the second
step, the 3′miR30-PGK-Venus fragment was inserted between the shRNA and
the sensor cassette. The ERC reporter cell line was as reported (13).
Sensor Ping-Pong Assay. FACS sorting was performed on a BD FACSAria II
sorting system (BD Biosciences). Four-hundred million cells were infected
with the virus library to ensure 1,000-fold representation with single-copy
integration of each virus. After selection by G418 (0.5 mg/mL), three cycles
of Ping-Pong sorting were performed. In the “Ping” step, after treating the
cells with Dox for 7 d, the cells were sorted to select for the low Venus
population. In the “Pong” step, after 7 d of Dox withdrawal, cells were se-
lected for high Venus expression. At least 1,000-fold representation was
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Fig. 4. HCV-targeting shRNAs have low sensor scores in average than HIV-
and inﬂuenza A virus-targeting shRNAs. (A) Sensor score distribution of
shRNAs by viral strains. (B) GC content and nucleotides frequencies of the
four viral strains. (C) GC content and A/U ratio plot of 55 human RNA viruses
and the average of 498 top shRNAs from the sensor screen.
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maintained after each sort and similar number of cells were frozen for ex-
traction of genomic DNA. Five strong hairpins (top 5) and ﬁve weak hairpins
(bottom 5) were used to determine the gating of the FACS sorting (13).
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